BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Huang YH, Chang GC. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep 2022;12:9753. [PMID: 35697720 DOI: 10.1038/s41598-022-13102-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Stridfeldt F, Cavallaro S, Hååg P, Lewensohn R, Linnros J, Viktorsson K, Dev A. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects by Epidermal growth factor inhibitor treatments.. [DOI: 10.1101/2022.10.14.512252] [Reference Citation Analysis]
2 Saw SP, Ng WP, Zhou S, Lai GG, Tan AC, Ang M, Lim W, Kanesvaran R, Ng QS, Jain A, Tan WL, Rajasekaran T, Chan JW, Teh YL, Pang M, Yeo J, Takano A, Ong B, Tan E, Tan SH, Skanderup AJ, Tan DS. PD-L1 score as a prognostic biomarker in Asian early-stage EGFR-mutated lung cancer. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.10.012] [Reference Citation Analysis]
3 Mansouri S, Heylmann D, Stiewe T, Kracht M, Savai R. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. Elife 2022;11:e79895. [PMID: 36074553 DOI: 10.7554/eLife.79895] [Reference Citation Analysis]
4 Teranishi S, Sugimoto C, Nagaoka S, Nagayama H, Segawa W, Miyasaka A, Hiro S, Kajita Y, Maeda C, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib. Thoracic Cancer. [DOI: 10.1111/1759-7714.14608] [Reference Citation Analysis]